Esteves-Jaramillo A, Herbas RIMJ, López-Collada VR

Idioma: Español
Referencias bibliográficas: 17
Paginas: 192-196
Archivo PDF: 173.80 Kb.

RESUMEN

Se reporta el caso de dos lactantes que presentaron parálisis flácida aguda (PFA) con secuelas neurológicas después de 60 días del inicio de la parálisis. Ambos pacientes con antecedente de haber recibido la primera dosis de la vacuna oral contra poliomielitis. El estudio de búsqueda de poliovirus en heces, reportó la presencia de alguna cepa vacunal, por lo que fueron clasificados como casos de poliomielitis paralítica asociada a vacunación (PPVA).

REFERENCIAS (EN ESTE ARTÍCULO)

1. Cochi SL, Linkins RW. The final phase of polio eradication: new vaccines and complex choices. J Infect Dis 2012;205(2):169-71.

2. Henderson DA, Witte JJ, Morris L, Langmuir AD. Paralytic Disease Associated with Oral Polio Vaccines. JAMA 1964;190:41-8.

3. Schonberger LB, McGowan JE, Jr., Gregg MB. Vaccineassociated poliomyelitis in the United States, 1961-1972. Am J Epidemiol 1976;104(2):202-11.

4. Sutter RW, Brink EW, Cochi SL, et al. A new epidemiologic and laboratory classification system for paralytic poliomyelitis cases. Am J Public Health 1989;79(4):495-8.

5. Vacunacion CNd. Eventos Temporalmente Asociados a la Vacunacion. Manual de Procedimientos Tecnicos. In: Infancia PdA, ed. Mexico, D.F.: Secretaria de Salud; 2002.

6. Stolley PD, Joseph JM, Allen JC, Deane G, Janney JH. Poliomyelitis associated with type-2 poliovirus vaccine strain. Possible transmission from an immunised child to a nonimmunised child. Lancet 1968;1(7544):661-3.

7. Albrecht RM. Poliomyelitis from a vaccinee. Lancet 1968;1(7556):1371.

8. The relation between acute persisting spinal paralysis and poliomyelitis vaccine (oral): results of a WHO enquiry. Bull World Health Organ 1976;53(4):319-31.

9. The relation between acute persisting spinal paralysis and poliomyelitis vaccine--results of a ten-year enquiry. WHO Consultative Group. Bull World Health Organ 1982;60(2):231-42.

10. Esteves K. Safety of oral poliomyelitis vaccine: results of a WHO enquiry. Bull World Health Organ 1988;66(6):739-46.

11. Aylward RB, Cochi SL. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission. Bull World Health Organ 2004;82(1):40-6.

12. 12. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992;14(2):568-79.

13. 13. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997;46(RR- 3):1-25.

14. Wattigney WA, Mootrey GT, Braun MM, Chen RT. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Pediatrics 2001;107(5):E83.

15. Recommendations of the Advisory Committee on Immunization Practices: revised recommendations for routine poliomyelitis vaccination. MMWR Morb Mortal Wkly Rep 1999;48(27):590.

16. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. MMWR Morb Mortal Wkly Rep 2009;58(30):829-30.

17. Andrus JK, Strebel PM, de Quadros CA, Olive JM. Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-91. Bull World Health Organ 1995;73(1):33-40.